Loading...
Projects / Programmes source: ARIS

Razvoj avtolognih tumorskih vakcin (Slovene)

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B007  Biomedical sciences  Medicine (human and vertebrates) 
B500  Biomedical sciences  Immunology, serology, transplantation 
Keywords
cancer, biological therapies, tumor vaccines, gene therapy, malignant melanoma, BRM - biological response modifiers
Evaluation (rules)
source: COBISS
Researchers (16)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  10331  PhD Tatjana Avšič-Županc  Microbiology and immunology  Researcher  2000 - 2001  802 
2.  18299  PhD Urška Čegovnik Primožič  Biochemistry and molecular biology  Researcher  1996 - 2001  37 
3.  03289  Jožica Červek  Oncology  Researcher  1999 - 2001  205 
4.  10337  PhD Alojz Ihan  Microbiology and immunology  Researcher  1996 - 2001  1,456 
5.  09170  Janez Jančar  Oncology  Researcher  2000 - 2001  84 
6.  12022  PhD Barbara Jezeršek Novaković  Oncology  Researcher  1996 - 2001  333 
7.  08751  Elga Majdič  Oncology  Researcher  1999 - 2001  57 
8.  03171  PhD Aleksandra Markovič-Predan  Medical sciences  Researcher  1999 - 2001  284 
9.  04377  Tadeja Movrin-Stanovnik  Oncology  Researcher  1998 - 2001  31 
10.  08007  PhD Srdjan Novaković  Oncology  Head  1999 - 2001  497 
11.  12230  Franc Pompe  Oncology  Researcher  1999 - 2001  44 
12.  08750  PhD Zvonimir Rudolf  Oncology  Researcher  1999 - 2001  258 
13.  08800  PhD Gregor Serša  Oncology  Researcher  1996 - 2001  1,518 
14.  12250  PhD Marko Snoj  Oncology  Researcher  2000 - 2001  195 
15.  15836  MSc Bogdan Umek  Oncology  Researcher  2000 - 2001  12 
16.  04890  PhD Branka Wraber  Microbiology and immunology  Researcher  2000 - 2001  266 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,750 
2.  0381  University of Ljubljana, Faculty of Medicine  Ljubljana  1627066  48,543 
Abstract
The current project is aimed at the development of autologous tumor vaccines expected to trigger a specific antitumor immune response. For the preparation of such vaccines we use two different approaches: Firstly, we create two-component autologous tumor vaccines by simple mixing autologous - syngeneic lethally irradiated tumor cells with a pleiotropic biological response modifier - MVE-2. The irradiated tumor cells are supposed to provide a sufficient quantity of tumor antigens, while the imunomodulator MVE-2 should at least multiply the number of cytotoxic macrophages that play a crucial role in the antitumor activity of the immune system together with CTL. Secondly, genetically manipulated autologous tumor cells are employed for the creation of another type of tumor vaccines. Namely, genes coding for various cytokines (TNF-a, IL-2, IFN-?) or growth factor (GM-CSF) are being transferred by means of molecular biology techniques into autologous tumor cells which are then lethally irradiated and utilized as tumor vaccines. The role of autologous tumor cells is thus similar to the one in two-component vaccines, with the difference that tumor cells in genetically manipulated vaccines also serve as a temporary source of cytokine or growth factor production. Cytokine or growth factor fabricated this way then stimulate the cellular antitumor immune response. The main tumor model used to evaluate the effectiveness of tumor vaccines is the intraperitoneal B-16 malignant melanoma in C57Bl/6 mice. Our interest is primarily centered on the effectiveness of vaccines in the prevention of tumor development owing to the fact that we see the prospective use of tumor vaccines as adjuvant therapy after surgery.
Views history
Favourite